Rating Change
Truist Securities reiterated its Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) on August 12, 2026.
reiterateNASDAQ:BBIO
Truist Securities Reiterates Buy Rating on BridgeBio Pharma, Inc. (BBIO)
Truist Securities reiterated its Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) on August 12, 2026.
At publication ·
What changed
BridgeBio Pharma, Inc. (NASDAQ:BBIO) · reiterate
- Firm
- Truist Securities
- Rating
- Buy to Buy
- Price at event
- $83.84
- Market capitalization
- $14.1B
At a glance
Key takeaways
- Truist Securities reiterated a Buy rating on BridgeBio Pharma (BBIO) on August 12, 2026, with the stock trading at $83.84 and a market capitalization of $14.1 billion.
Market Context
BridgeBio Pharma, Inc. operates in the Healthcare sector. The stock currently trades at $83.84 with a market capitalization of $14.1B. The stock has gained 73.5% over the past 52 weeks.
Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BridgeBio Pharma, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for BridgeBio Pharma, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 12, 2026 | Truist Securities | Buy | N/A |
| Aug 12, 2026 | JP Morgan | Overweight | N/A |
| Aug 11, 2026 | Wells Fargo | Overweight | N/A |
| Aug 11, 2026 | Piper Sandler | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View BBIO Stock Page
Frequently Asked Questions
What does the Buy rating mean for BBIO?
A rating of Buy from Truist Securities reflects the analyst's outlook on BridgeBio Pharma, Inc. (NASDAQ:BBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BBIO forecast page.
